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Abstract
Background: An inflammatory reaction in the airways and lung parenchyma, comprised mainly of neutrophils and
alveolar macrophages, is present in some patients with chronic obstructive pulmonary disease (COPD). Thoracic
fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) has been proposed as a promising imaging
biomarker to assess this inflammation. We sought to introduce a fully quantitative analysis method and compare this
with previously published studies based on the Patlak approach using a dataset comprising 18F-FDG PET scans from
COPD subjects with elevated circulating inflammatory markers (fibrinogen) and matched healthy volunteers (HV).
Dynamic 18F-FDG PET scans were obtained for high-fibrinogen (>2.8 g/l) COPD subjects (N = 10) and never
smoking HV (N = 10). Lungs were segmented using co-registered computed tomography images and
subregions (upper, middle and lower) were semi-automatically defined. A quantitative analysis approach was
developed, which corrects for the presence of air and blood in the lung (qABL method), enabling direct
estimation of the metabolic rate of FDG in lung tissue. A normalised Patlak analysis approach was also
performed to enable comparison with previously published results. Effect sizes (Hedge’s g) were used to
compare HV and COPD groups.
Results: The qABL method detected no difference (Hedge’s g = 0.15 [−0.76 1.04]) in the tissue metabolic rate of FDG
in the whole lung between HV (μ = 6.0 ± 1.9 × 10−3 ml cm−3 min−1) and COPD (μ = 5.7 ± 1.7 × 10−3 ml cm−3 min−1).
However, analysis with the normalised Patlak approach detected a significant difference (Hedge’s g = −1.59 [−2.57
−0.48]) in whole lung between HV (μ = 2.9 ± 0.5 × 10−3 ml cm−3 min−1) and COPD (μ = 3.9 ± 0.7 × 10−3 ml cm−3 min−1).
The normalised Patlak endpoint was shown to be a composite measure influenced by air volume, blood volume and
actual uptake of 18F-FDG in lung tissue.
Conclusions: We have introduced a quantitative analysis method that provides a direct estimate of the metabolic rate
of FDG in lung tissue. This work provides further understanding of the underlying origin of the 18F-FDG signal in the
lung in disease groups and helps interpreting changes following standard or novel therapies.
Keywords: PET, 18F-FDG, Lung inflammation, Modelling, COPD
* Correspondence: christopher.coello@gmail.com
†Equal contributors
1Imanova Ltd., Centre for Imaging Sciences, Hammersmith Hospital, London,
UK
2Division of Brain Sciences, Department of Medicine, Imperial College
London, London, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Coello et al. EJNMMI Research  (2017) 7:47 
DOI 10.1186/s13550-017-0291-2
Background
Chronic obstructive pulmonary disease (COPD) is the
third leading cause of death globally and is associated
with significant morbidity and healthcare utilisation
[1]. It is characterised in some patients by airflow
limitation and persistent inflammation in the airways
and lungs [2].
Thoracic18F-fluorodeoxyglucose (18F-FDG) positron
emission tomography co-registered with computed tom-
ography (PET/CT) has been proposed as a promising
imaging modality [3] to investigate pathological pro-
cesses, disease phenotype and pathophysiology and po-
tentially evaluate novel therapies in COPD [4]. The
metabolic rate constant derived from dynamic 18F-FDG
tissue uptake in tissue has been shown to be a good
marker of glycolytic activity in brain [5] and myocardial
metabolism. An increased metabolic rate of 18F-FDG has
previously been observed in COPD subjects vs controls
[6–8], and this has been hypothesised to be a surrogate
of pulmonary inflammation. In vitro assays of COPD
lung tissue have shown that an increased metabolic ac-
tivity is associated with primed and activated neutrophils
[9], which are thought to drive inflammation in COPD
patients.
Estimation of the 18F-FDG metabolic rate in lung tis-
sue is the required parameter for assessing lung inflam-
mation [10]. However, accurate measurement of the
lung tissue metabolic rate is confounded by the presence
of air and blood activity [11] in the region of interest
(ROI). The presence of air in the lungs contributes to a
reduction in the measured lung ROI activity as a conse-
quence of partial volume effects [12, 13]. The presence
of blood contributes a background radioactive signal to
the lung ROI, artificially increasing the measured signal.
Estimation of the amount of air can be obtained
using a co-registered attenuation correction CT (CT-
AC) [12]. Methodology to correct the 18F-FDG lung
uptake for air and blood contribution has been ap-
plied previously to patients with focal patterns of lung
fibrosis [10]. In more diffuse diseases like COPD or
asthma, quantification of 18F-FDG has been analysed
using a Patlak graphical approach to estimate a meta-
bolic activity outcome measure where the Patlak
intercept is used as a surrogate to correct for air vol-
ume [14]. These previous studies [6–8] employing the
Patlak method did not specifically include any correc-
tion for blood activity to the lung ROI. Additionally,
the use of the Patlak intercept to correct for the
amount of air in the lungs has not been validated.
In this work, we sought to introduce a quantitative
tracer kinetic analysis method that corrects for the pres-
ence of air and blood in the lung (qABL method), enab-
ling a more accurate measurement of the lung tissue
uptake of 18F-FDG. We compared this with the
previously published normalised Patlak approach using a
dataset comprising 18F-FDG PET scans from COPD sub-
jects with elevated circulating inflammatory markers (fi-
brinogen), a recently qualified biomarker associated with
exacerbations and mortality in COPD [15] and matched
healthy never smokers (HV).
Theory
The measured radioactivity concentration in a region of
the lung can be expressed as the sum of three terms that
reflect blood, tissue and air:
CM tð Þ ¼ VBCB tð Þ
þ 1−VB−VAð ÞCT t;K1; k2; k3;CBð Þ
þ VACA tð Þ ð1Þ
where CM(t) is the measured radioactivity concentration,
CB(t) is the radioactivity concentration in blood, CT(t) is
the radioactivity concentration in tissue, CA(t) is the
radioactivity concentration in air, VA is the fractional air
volume in the ROI, VB is the fractional blood volume in
the ROI, and K1, k2, k3 are the compartmental model’s
microparameters. For radiotracers administered intra-
venously such as 18F-FDG, the radioactivity concentra-
tion in air (CA(t)) can be considered negligible and so
the third term of Eq. (1) is zero. The kinetics of 18F-FDG
in tissue have been shown to be well described in
humans by an irreversible two tissue compartmental
model [16] with the metabolic rate constant (Ki ¼ K1k3k2þk3)
of 18F-FDG being the outcome measure of interest.
Using the measured activity in the ROI (CM(t)) and in
blood (CB(t)), least square estimation of the five model
parameters (K1, k2, k3,VA,VB) leads to problems of nu-
merical unidentifiability. However, VA can be estimated
independently using CT imaging [12]. The proposed
method uses this estimate of VA (denoted VCTA ) in Eq.
(1). This leaves four parameters to be estimated from fit-
ting to the dynamic PET data similar to the general
model for dynamic brain PET data [17] with the excep-
tion that the tissue term is weighted by ð1−VB−VCTA Þ in-
stead of (1 −VB):
CM tð Þ ¼ VBCB tð Þ
þ 1−VB−VCTA
 
CT t;K1; k2; k3;CBð Þ ð2Þ
Methods
The study is being conducted in accordance with Good
Clinical Practice standards. The participating sites re-
ceived favourable opinion from the local ethics commit-
tee and approval from the Administration of Radioactive
Substances Advisory Committee. All patients provide in-
formed written consent before enrolment in accordance
with the Declaration of Helsinki.
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Patients and healthy volunteers
Baseline dynamic 18F-FDG PET/CT scans obtained from
the EVOLUTION (COPD, N = 10) and the EVOLVE
(HV, N = 10) studies were used for this methodological
assessment. The subset of ten subjects with COPD from
EVOLUTION were chosen to be matched for age and
gender with the ten HV used from EVOLVE. These
COPD subjects were aged between 50 and 85 years, with
a body mass index less than 35 kg/m2 and a plasma fi-
brinogen level greater than 2.8 g/l at screening. The
same acquisition protocol was applied in all scans.
The EVOLUTION trial (Evaluation of losmapimod in
COPD patients stratified by fibrinogen [18], Clinical-
Trials.gov, NCT01541852) is a double-blinded placebo-
controlled multicentre randomised controlled trial which
incorporates 18F-FDG PET/CT imaging of the lungs,
aorta and carotids at baseline and approximately
16 weeks following treatment with losmapimod (p38
mitogen-activated protein kinase inhibitor: (GW856553,
GlaxoSmithKline, Brentford, UK)) or placebo.
The EVOLVE study (REC 13/EE/0165, UK CRN
ID 1513) is a cross-sectional multicentre study de-
signed to evaluate lung and vascular inflammation
by imaging subjects with COPD secondary to
cigarette smoke compared with subjects with COPD
secondary to alpha-1 antitrypsin deficiency and to
compare these with subjects with obstructive sleep
apnoea, healthy smokers and healthy never smoking
controls (HV).
Image acquisition
Each subject underwent a low-dose CT scan and a 60-min
dynamic 18F-FDG PET scan following a bolus injection of
237.3 ± 10.4 MBq (2.81 ± 0.54 MBq/kg) of radiotracer (full
details of the image acquisition are provided in Additional
file 1).
Image processing
The analysis pipeline (Fig. 1) was common to all PET-CT
data. Except for the whole lung and pulmonary artery seg-
mentation, the post-processing of the images and kinetic
modelling was achieved using the Molecular Imaging and
Kinetic Analysis Toolbox (MIAKAT™, www.miakat.org), a
Matlab (The MathWorks Inc., Natick, MA, USA) toolbox.
Description of the delineation of the whole lung (WL)
mask can be found in the Additional file 1.
Regional time activity curves (TACs)
To study regional differences of 18F-FDG uptake, the
downsampled WL mask was automatically subdivided
into three regions of similar volume along the axial dir-
ection. The upper (UL), middle (ML) and lower (LL)
lung masks were generated so that approximately each
region equals one third of the total whole lung mask vol-
ume. Using the WL mask and the three subdivisions
mentioned above, four time activity curves (TACs) were
generated by calculating the mean regional activity for
each time frame of the dynamic PET.
Fig. 1 Overview of the kinetic modelling approaches implemented in this paper to analyse dynamic 18F-FDG lung PET data
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The standard uptake value (SUV) outcome measure was
calculated for each TAC by dividing the average activity be-
tween 30 and 60 min by the injected dose per kg (kBq/kg).
CT-derived estimation of the fractional air volume
At the regional level, the fractional air volume in a given
region R (WL, UL, ML and LL) was estimated [12]:
VCTA ¼ 1−
HUR−HUair
 
HU tissue−HUairð Þ ð3Þ
where VCTA is the estimated fractional air volume, HUR
is the mean Hounsfield Unit (HU) in region R, HUair is
the HU of air (−1024), and HUtissue is an approximation
of the HU of lung tissue (40, taken from [12]). The air
volume in a region can be computed by multiplying
VCTA by the volume of the region.
Estimation of the lung input function
An image-derived input function (IDIF) was estimated
as follows: a volume of interest was defined in the de-
scending aorta (DA). Guided by an averaged early frame
(0–5 min) PET and the downsampled CT-AC, the centre
of the DA was manually drawn on a slice-by-slice basis
(axial slices) using a 1-cm (5 voxel)-diameter disk mask
starting at the aorta arch. To minimise the partial volume
effect, the ROI was drawn very centrally in the DA over a
large range of axial slices. The aorta mask was then ap-
plied to the dynamic PET image, and the DA time activity
curve (TAC) was extracted. The actual blood input func-
tion used, CB(t), included a correction for the plasma to
whole blood ratio (1.056 ± 0.015) which was determined
from venous samples collected after 5 min.
For each scan, a global time delay was estimated to ac-
count for the time separation between the radioactivity
passing in the tissue of interest and the descending
aorta: for delays spanning from −50 to 50 s, a one tissue
compartmental model was fitted between the first 5 min
of the delayed blood IF and the first 5 min of the WL
TAC. The estimated delay was the delay generating the
lowest residual sum of squares on the model fit.
Kinetic modelling
Kinetic modelling was performed combining Eq. (2)
(that describes the tissue concentration of FDG within
the ROI composed of air, blood and tissue) with the irre-
versible two tissue compartmental model describing the
kinetics of FDG in the lung tissue itself. Combining
these two levels of description is necessary to accurately
estimate the metabolic rate of FDG in lung tissue only
(Fig. 2). Because the method is a quantitative analysis
correcting for air and blood in lung tissue, the acronym
qABL will be used to refer to this method.
The irreversible two tissue compartmental model
(Fig. 2) is composed of a component with reversible
kinetics characterised by the rate constant K1 and k2
and a component with irreversible kinetics (k3). The
qABL method was implemented using a fitted frac-
tional blood volume contribution leading to the esti-
mation of four parameters (K1, k2, k3,VB) that were
obtained by weighted least squares fitting. The
Fig. 2 Axial (left), coronal (middle) and sagittal (right) slices for the CT-AC (first and second row) and the averaged (30–60 min) SUV (third row) and
Patslope (fourth row) parametric images of a representative COPD patient (M, 66 years). The axial slice was chosen in the upper part of the lung as
being representative of tissue loss in COPD. CT-AC: computed tomography attenuation correction, SUV: standardised uptake value
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metabolic rate constant of 18F-FDG corrected for air
and blood, Ki (ml cm
−3 min−1), was then calculated
as
Ki ¼ K1k3k2 þ k3 ð4Þ
To enable comparison with previous studies [6–8], the
Patlak graphical analysis [19] was also implemented with
a linear start time (t*) fixed to 10 min. The slope (Pat-
slope) and the intercept (Patintcpt) of the regression were
extracted. The normalised metabolic rate nKPati , used in
previous studies [6–8] for quantifying lung tissue metab-
olism, was calculated as the ratio between the slope and
intercept was calculated. As a consequence of the ROI
containing air and blood (see Appendix 1), the outcome
parameter nKPati is a composite measure that includes
terms for the fractional air volume, fractional blood vol-
ume and the metabolic rate of 18F-FDG in lung tissue:
nKPati ¼
Patslope
Patintcpt
¼ 1−VB−VAð ÞKi
1−VB−VAð ÞV ss þ VB ð5Þ
with Ki being the tissue metabolic rate constant of 18F-
FDG and Vss the steady-state partition coefficient be-
tween tissue and plasma of non-phosphorylated FDG.
Statistics
Differences between groups were assessed using the
standardised corrected (or unbiased) effect size calcu-
lated using the Hedge’s g (abbreviated g) metric reported
with the analytical 95% confidence interval (CI) mea-
sured using the Measures of Effect Size Toolbox [20].
Effect sizes are defined as small (g ≤ 0.2), medium (0.2 <
g ≤ 0.8) and large (0.8 < g). Correlation was measured
using Pearson’s correlation coefficient reported with the
analytical 95% CI. A null hypothesis of zero effect be-
tween groups was rejected if the 95% CI did not contain
the value 0. In this case, the group difference was named
significant.
Results
Demographics of the two cohorts are reported in
Table 1.
The difference in density in the lungs observed on the
CT (Fig. 2) is also observable on the SUV and Patslope
images illustrating the need to account for lung density.
Figure 3 shows a representative TAC of a HV subject
and the model fit obtained using the qABL method. Dif-
ferent metrics derived from CT (VCTA ), static PET (SUV)
and dynamic PET (Patslope, Patintcpt, nKPati , Ki,VB) images
are reported in Table 2 for the whole lung and upper,
middle and lower subregions. For each metric and re-
gion, the mean (μ) and coefficient of variation (CoV(%)
= 100 × σ/μ where σ is the standard deviation of the
metric) are reported.
Metabolic rate of 18F-FDG in HV and COPD subjects
The metabolic rate of glucose estimated using the qABL
method (Ki) and the Patlak analysis (nKPati ) are displayed
in Fig. 4 for each subject in the HV and COPD groups.
There was no significant difference in whole lung meta-
bolic rate constant (Ki) between the HV (N = 10, μ = 6.0 ±
1.9 × 10−3 ml cm−3 min−1) and COPD (N = 10, μ = 5.7 ±
1.7 × 10−3 ml cm−3 min−1) groups when estimated using
the qABL method. The measured effect size was small in
both the whole lung (g = 0.15 [−0.76 1.04]) and in the
upper lung (UL: g = 0.31 [−0.61 1.20]).
In contrast, with the Patlak analysis, there was a signifi-
cant difference in whole lung nKPati which was lower in the
HV (N = 10, μ = 2.9 ± 0.5 × 10−3 ml cm−3 min−1) compared
to COPD (N = 10, μ = 3.9 ± 0.7 × 10−3 ml cm−3 min−1)
groups, with a large effect size (g = −1.59 [−2.57 −0.48]). A
similarly large effect size was measured when the ROI was
restricted to the upper lung (UL: g = −1.42 [−2.38 −0.35]).
Fractional air and blood volume
The CT-derived fractional air volume (Table 2 and
Fig. 5a) was, as expected, higher in COPD compared to
HV (WL: g = −1.69 [−2.68 −0.56], UL: g = −1.15 [−2.08
−0.12]) consistent with the presence of emphysema in
COPD. As a consequence, the fraction of the non-air
(blood and tissue) component was smaller in COPD
subjects than in HV. The fractional blood (VB) and the
fractional tissue volume ð1−VCTA −VBÞ were lower in
COPD than in HV (Table 2, Fig. 5b, c), with a large ef-
fect size for both the WL (blood: g = 0.71 [−0.25 1.61],
tissue: g = 1.10 [0.08 2.02]) and UL (blood: g = 0.71
[−0.25 1.61]). Medium effect size was measured for the
fractional tissue volume in the UL (g = 0.63 [−0.32 1.53]).
Finally, medium effect size (WL: g = −0.21 [−0.70 1.10],
Fig. 5d) in the tissue to blood ratio ( ð1−VCTA Þ=VB−1 )
was observed between COPD and HV with no signifi-
cant difference between groups.
Table 1 Demographics of the HV and the COPD cohorts
HV COPD
Age (years) 70 ± 7 71 ± 7
Gender (M/F) 09/01 08/02
Smokers (%)a 0 10
Mean total pack years (years) 0 42 ± 6
Body mass index (kg/m2) 26.4 ± 2.81 27.6 ± 4.20
FEV1 (l) 2.88 ± 0.64 1.39 ± 0.33
FEV1 (% predicted) 103 ± 15 48 ± 12
FEV1 forced expiratory volume in 1 s
a% of current smokers (the rest being ex-smokers)
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Patlak intercept
Because both the qABL and Patlak analysis were imple-
mented on the same dataset, the relationship between
the Patlak intercept and the fractional blood volume
could be investigated. The scatter plot showing the rela-
tionship between the Patlak intercept (Patintcpt) is shown
in Fig. 6. The relationship between these variables is
shown in Eq. A14 of Appendix 1. A significant correl-
ation (WL: r = .56 [.16 .80], UL: r = .78 [.51 .91]) of the
Patlak intercept to the fractional blood volume (VB) was
measured.
Discussion
The objective of this work was to introduce a quantitative
method (noted qABL) for the measurement of the metabolic
rate of 18F-FDG in lung tissue and to compare this with the
previously published normalised Patlak approach using a
dataset comprising 18F-FDG PETscans from COPD subjects
with evidence of circulating inflammation (i.e. elevated cir-
culating fibrinogen) and matched healthy volunteers.
The proposed qABL approach permits the direct esti-
mation of the metabolic rate of 18F-FDG (Ki) in lung tissue
by appropriately correcting for the confounding
Fig. 3 Left: representative TAC of a HV subject and estimated components obtained using the qABL method. Right: graphical
representation of the different components involved in the qABL method: air, blood and tissue (tissue being modelled by an
irreversible 2TC model for 18F-FDG)
Table 2 Parameter values across HV (N = 10) and COPD (N = 10) subjects in four lung ROIs
Whole lung Upper lung Middle lung Lower lung
HV COPD HV COPD HV COPD HV COPD
VA
CT
μ 0.72 0.79 0.74 0.80 0.72 0.79 0.68 0.78
CoV (%) 6.0 5.2 5.0 7.3 6.0 5.1 7.7 4.4
SUV
μ 0.63 0.45 0.60 0.45 0.62 0.45 0.68 0.45
CoV (%) 20 26 18 37 21 25 20 25
Patslope
μ (×10−3) 0.61 0.51 0.54 0.52 0.57 0.51 0.73 0.50
CoV (%) 21 22 30 35 26 22 31 33
Patintcpt
μ 0.21 0.13 0.21 0.13 0.21 0.13 0.23 0.13
CoV (%) 13 26 12 38 14 24 17 26
nKi
Pat
μ (×10−3) 2.9 3.9 2.7 4.1 2.72 3.9 3.4 3.8
CoV (%) 19 18 31 28 23 18 42 31
Ki
μ (×10−3) 6.0 5.7 7.2 6.3 5.9 6.2 5.4 4.8
CoV (%) 32 29 42 37 32 35 46 40
VB
μ 0.14 0.11 0.15 0.12 0.15 0.12 0.11 0.10
CoV (%) 18 36 18 49 18 37 27 26
VCTA fractional air volume measured using CT-AC, SUV standardised uptake value, Pat
slope Patlak slope, Patintcpt Patlak intercept, nKPati ratio Pat
slope/Patintcpt, Ki air
and blood corrected metabolic rate of 18F-FDG in lung tissue, VB fractional blood volume
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contributions of air and blood. The inclusion of the esti-
mation of the fractional air volume in the general Eq. (2)
differs from a previously published method [10] by avoid-
ing division of the parameters of interest (e.g. Ki or VT) by
a correction factor that approaches 0. Thus, when the
fraction of air increases, the method presented here will
avoid artefactual increase of Ki in regions with emphy-
sema. In addition, the model chosen for the tissue kinetics
(in the term CT(t,K1, k2, k3,CB) of Eq. (2)) can be tailored
to individual tracers enabling this methodology to be ap-
plied widely for quantitative PET lung imaging.
The proposed qABL method presented here shows no dif-
ference in the estimated metabolic rate of 18F-FDG (Ki) be-
tween HV and high-fibrinogen COPD subjects in contrast to
previously published studies containing a similar numbers of
subjects using Patlak analysis [6–8]. Since inflammatory pro-
cesses in the lung parenchyma in COPD have been widely
described in the literature [21] and our measurements show
no difference between healthy volunteers and COPD pa-
tients, we can infer that whole lung FDG may simply be in-
sufficiently sensitive to detect the increased inflammation.
Applying the normalised Patlak approach ( nKPati ) as
used in three prior studies [6–8] to our dataset, we were
able to replicate the magnitude of previously observed
group differences between HV and high-fibrinogen
COPD subjects (Table 3) with similar effect sizes.
Nevertheless, in Appendix 1, we theoretically show
that the normalised Patlak outcome measure includes
terms for blood and air volume that introduce a bias.
For example, in the absence of differences in Ki, we
show in Appendix 2 that changes in VB and VA observed
in COPD lead to an artefactual ~30% increase in nKPati .
Thus, nKPati is not a direct measure of the lung tissue
metabolic rate but is rather a composite outcome meas-
ure sensitive to changes in Ki, VB and VA, which makes
it difficult to interpret. It may reflect disease severity and
thus correlate with other disease severity biomarkers,
but this correlation could be driven by any combination
of differences in Ki,VB and/or VA.
The difference observed using normalised Patlak ( n
KPati ) might be driven by the other quantities VB and/or
VA to which it is sensitive. When using normalised
Fig. 4 Metabolic rate of 18F-FDG in the whole lung (top) and the upper lung (bottom) estimated with normalised Patlak (left) and qABL method
(right) in HV and COPD cohorts. Individual points are plotted together with median, q1 (first quartile) and q3 (third quartile). Whiskers
extent: q3 − 1.5 * (q3 − q1) for the low boundary and q3 + 1.5 * (q3 − q1) for the high boundary
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Patlak (nKPati ) as an estimate of the metabolic rate, the
measured group difference between HV and COPD is
driven by the denominator Patintcpt (Table 2, HV = 0.21
± 0.03, COPD = 0.13 ± 0.05, g = 2.42 [1.11 3.53]) and not
by the numerator Patslope (Table 2, HV = 0.61 ± 0.13,
COPD = 0.51 ± 0.11, g = 0.64 [0.18 1.08]). Patintcpt is af-
fected by changes in the air and blood volume in the
ROI as shown in Eq. A13 of Appendix 1 and logically
presents a high correlation to the fractional blood
volume (VB) estimated with qABL method, giving fur-
ther evidence that the group difference measured with
normalised Patlak (g = −1.59 [−2.57 −0.48]) could be pri-
marily due to the difference in blood volume between
HV and COPD. Correction for blood using a fixed (not
fitted) blood volume contribution is possible with graph-
ical Patlak analysis, but this correction biases the out-
come parameters as the blood volume varies between
populations [22].
Fig. 5 Group comparison of the fractional air volume VCTA (a), fractional blood volume VB (b), fractional tissue volume (1−V
CT
A −VB) (c) and tissue to
blood ratio (d) parameters in the whole lung obtained with the qABL method
Fig. 6 Scatter plot showing the relationship between the intercept of the graphical Patlak analysis (Patintcpt) and the fractional blood volume (VB).
Left whole lung, Right upper lung, Blue squares HV, violet circles COPD
Coello et al. EJNMMI Research  (2017) 7:47 Page 8 of 12
Some limitations of the two-tissue irreversible (2TC)
model in lung tissues have been shown in preclinical
models of acute lung injury [23, 24], and a model with
an extra compartment (three-tissue irreversible (TEC)
model) has been proposed to overcome these limita-
tions. Schroeder et al. [23] proposed that lung kinetics
could be classified as 2TC-type or TEC-type (Figs. 3 and
4 of Schroeder et al.). The kinetics observed in our study
(Fig. 3) are of the 2TC-type, rather than the TEC-type,
consistent with the exclusion of co-existing pathologies
(i.e. acute lung injury) in our COPD population. If acute
lung injury patients were to be analysed with the qABL
method, a TEC model should be considered in place of
the 2TC irreversible.
ROI mis-registration due to respiratory and cardiac
cyclic movement [25] together with variability of the
fractional air volume VCTA due to the breathing cycle
[26] have been identified as two potential limitations of
the use of VCTA . The attenuation correction CT in this
study was acquired during free breathing to achieve an
average position of the lung. Higher air fraction in
COPD (0.79) than in HV (0.72) measured with VCTA is in
agreement with previous findings [22]. In addition, the
coefficient of variation of VCTA (Table 2) in the whole
lung for HV (6.0%) and COPD (5.2%) is low. These two
elements give us confidence that VCTA is a robust esti-
mate for the fraction of air in the lungs.
The current investigation was limited to a sample size
of 10 in each group, and so a change in the estimated Ki
obtained with the qABL method cannot be ruled out in
a larger study, although based on these data, if there is a
signal, it is likely to be small.
A possible avenue for further work would be to inves-
tigate focal regions (anatomical lobes, individual voxels)
where higher levels of inflammatory activity might be ex-
pected. For this purpose, either parametric images
should be used or manually delineated regions focussing
on specific pathology. Studying other populations with
different levels of pulmonary inflammation would also
give useful information and hence help us to understand
whether 18F-FDG has more general utility for imaging
lung inflammation. Correlation with systemic blood
markers of inflammation (e.g. neutrophils, fibrinogen),
with histology and with independent alternative mea-
sures of the quantities of interest, such as VB, would also
be valuable. These results also suggest that development
of other more specific tracers of the inflammatory
process in COPD may be beneficial.
Conclusions
We have introduced a quantitative method for the direct
estimation of the metabolic rate of 18F-FDG PET in lung
tissue that includes appropriate corrections for blood
radioactivity and air. This work provides further under-
standing of the underlying origin of the 18F-FDG signal
in the lung in disease groups and helps interpreting
changes following standard or novel therapies.
Appendix 1
In this appendix, the theoretical expression of the nor-
malised Patlak metric is derived for regions containing
air and blood.
The measure PET time activity from a region in the
lung is given by,
CM tð Þ ¼ VBCB tð Þ þ 1−VB−VAð ÞCT t;K 1; k2; k3;CBð Þ
ðA1Þ
where CB is the whole blood radioactivity concentration
and CT is the lung tissue radioactivity concentration (de-
scribed by the irreversible two tissue compartment
(2TC) model (Appendix Figure A1) with the micro pa-
rameters K1, k2 and k3).
Table 3 Comparison of nKi
Pat between our results and previously published
ROI HV COPD Group comparison
# Mean ± Std # Mean ± Std Abs diff. % change Effect size (g)
Ref [2] WL 8 3.0 ± 1.2 10 4.2 ± 1.6 1.2 +40% 0.79
This dataset WL 10 2.8 ± 0.4 10 3.9 ± 0.7 1.1 +39% 1.59
Ref [1] UL 9 4.5 ± 0.9 10 6.1 ± 1.6 1.6 +36% 1.15
This dataset UL 10 2.7 ± 0.8 10 4.1 ± 1.1 1.6 +64% 1.42
WL whole lung, UL upper lung
Fig. 7 Irreversible 2TC model
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The irreversible 2TC model is described by a set of
differential equations,
dC1 tð Þ
dt
¼ K 1CB tð Þ−k2C1 tð Þ−k3C1 tð Þ ðA2Þ
dC2 tð Þ
dt
¼ k3C1 tð Þ ðA3Þ
These differential equations can be solved using the
method of Laplace transform to derive the following
analytical solutions,
C1 tð Þ ¼ K 1e− k2þk3ð Þt⊗CB tð Þ ðA4Þ
C2 tð Þ ¼ K1k3k2 þ k3 1−e
− k2þk3ð Þt
 
⊗CB tð Þ ðA5Þ
where ⊗ is the convolution operator. The total tissue
signal CT(t) (=C1(t)+C2(t)) is given by,
CT tð Þ ¼ K1k2k2 þ k3 e
− k2þk3ð Þt þ K1k3
k2 þ k3
 
⊗CB tð Þ
ðA6Þ
The standard Patlak equation consistent with the irre-
versible 2TC 18F-FDG model can be derived by rearran-
ging equation (A6) as,
CT tð Þ ¼ Ki
Z t
0
CB τð Þdτ þ k2k2 þ k3 C1 tð Þ ðA7Þ
where
Ki ¼ K1k3k2 þ k3
Substituting (A7) into (A1) and dividing by CB(t)
yields,
CM tð Þ
CB tð Þ ¼ VB þ 1−VB−VAð Þ Ki
Z t
0
CB τð Þdτ
CB tð Þ þ
k2
k2 þ k3
C1 tð Þ
CB tð Þ
2
664
3
775
ðA8Þ
The Patlak method assumes that the free 18F-FDG in
tissue has reached its steady state after a time t*, such
that,
C1 tð Þ
CB tð Þ

t>t
¼ K 1
k2 þ k3 ðA9Þ
Substituting (A9) into (A8) yields,
CM tð Þ
CB tð Þ ¼ VB þ 1−VB−VAð Þ Ki
Z t
0
CB τð Þdτ
CB tð Þ þ
K1k2
k2 þ k3ð Þ2
2
664
3
775
ðA10Þ
which simplifies to,
CM tð Þ
CB tð Þ ¼ 1−VB−VAð ÞV ss þ VB
þ 1−VB−VAð ÞKi
Z t
0
CB τð Þdτ
CB tð Þ ðA11Þ
where
Vss ¼ K 1k2
k2 þ k3ð Þ2
Thus, when applying the Patlak analysis method of the
form,
CM tð Þ
CB tð Þ ¼ Pat
slope
Z t
0
CB τð Þdτ
CB tð Þ þ Pat
intcpt ðA12Þ
to lung data, it can be shown (by equating (A11) and
(A12)) that the actual measured slope and intercept are:
Patslope ¼ 1−VB−VAð ÞKi ðA13Þ
Patintcpt ¼ 1−VB−VAð ÞVss þ VB ðA14Þ
Thus the normalized Patlak outcome measure
nKPati ¼ Pat
slope
Patintcpt
 
can be shown to be a composite par-
ameter that includes terms for fractional blood volume
(VB), fractional air volume (VA) and the metabolic rate
of glucose in lung tissue (Ki).
nKPati ¼
Patslope
Patintcpt
¼ 1−VB−VAð ÞKi
1−VB−VAð ÞVss þ VB ðA13Þ
Appendix 2
Application of Appendix 1: theoretical prediction of the
group difference between HV and COPD groups when
there is an absence of difference of metabolic rate of
18F-FDG in tissue i.e. Ki(HV) = Ki(COPD).
Fractional air volume (VA) and fractional blood volume
(VB) estimates were obtained from previously published
quantitative H2
15O and C15O scans25:
 HV
: VA = 0.74, VB = 0.16
 COPD
: VA = 0.85, VB = 0.08
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An estimate of Ki and Vss from the healthy volunteers
was derived from Table 2:
 Ki = 6.10 x 10-3 ml.cm-3.min-1
 Vss = 0.50 ml.cm-3
These parameters were fixed for both HV and COPD
with only VA and VB being altered between the groups.
For HV,
nKPati HVð Þ ¼
1−VB HVð Þ−VA HVð Þð ÞKi
1−VB HVð Þ−VA HVð Þð ÞV ss þ VB HVð Þ
¼ 2:9  10−3
For COPD,
nKPati COPDð Þ ¼
1−VB COPDð Þ−VA COPDð Þð ÞKi
1−VB COPDð Þ−VA COPDð Þð ÞV ss þ VB COPDð Þ
¼ 3:8  10−3
Theory predicts a 31% increase in nKPati for COPD
compared to HV in the absence of differences in the
metabolic rate of 18F-FDG in lung tissue.
Additional file
Additional file 1: Supplemental data for quantitative analysis of
dynamic 18F-FDG PET/CT for measurement of lung inflammation.
(DOCX 318 kb)
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